Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 20, 2009
Pharmacy Choice - Pharmaceutical News - FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis - November 20, 2009

Pharmacy News Article

 11/4/09 - FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis

An important assay used to aid in the diagnosis of rheumatoid arthritis (RA) will soon be available on Abbott's ARCHITECT immunoassay analyzers. The FDA has granted 510(k) clearance for an antibody cyclic-citrulinated peptide, or anti-CCP assay, to run on the world class systems (see also Arthritis).

Many patients with RA develop an immune response against proteins containing citrulline long before they present symptoms of the disease. Studies show detecting the level of these antibodies earlier in the disease continuum, in conjunction with other clinical information, is critical to the early diagnosis of the disease. The American College of Rheumatology treatment guidelines for RA recommends early diagnosis of the disease and timely introduction of therapies to prevent potentially irreversible joint damage.

The assay was developed by Axis-Shield to run on Abbott's ARCHITECT i1000SR and i2000SR systems. The anti-CCP assay is already approved and available on the Abbott ARCHITECT outside the United States.

"The approval of the anti-CCP assay for use on the ARCHITECT provides an important tool for physicians to aid in the early diagnosis of RA. We are pleased to add this assay to the existing panel of autoimmune disease biomarker assays currently available on the ARCHITECT and clinical chemistry platforms as we underscore Abbott's continued commitment to the area of immunology," said Michael Warmuth, senior vice president, diagnostics, Abbott.

Important Product Usage and Safety Information

The ARCHITECT Anti-CCP assay is a chemiluminescent microparticle immunoassay (CMIA) for the semi-quantitative determination of the lgG class of autoantibodies specific to cyclic citrullinated peptide (CCP) in human serum or plasma on the ARCHITECT i System. Detection of anti-CCP antibodies is used as an aid in the diagnosis of Rheumatoid Arthritis (RA) and should be used in conjunction with other clinical information. This product is for in vitro diagnostic use only. Use of this product requires the handling of human specimens, and it is recommended that all human-sourced materials be considered potentially infectious. This product contains sodium azide, and both the material and its container should be disposed of safely. Assay specific information is presented in the assay package insert which can be accessed at www.abbottdiagnostics.com once the product is available.



(c) 2009 Biotech Week via NewsRx.com

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 22: Oral Medications for Diabetes: Making the most out of the Treatment
Nov 23: Medication Errors Part I: Analyzing the Risks & Starting the Process
Dec 01: An Overview of Drug Interactions
Dec 04: Aplastic Anemia: A Primer for the Practicing Pharmacist
Dec 06: Introduction to HIV and Antiretroviral Drugs
Click for entire Webinar Calendar

Special Announcement

Free Membership
Click Here to register to Win an iPod nano.
Rules and Regulations
Enjoy Free CE, Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comRxProHealth.comRxTechSchool.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415